Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers. Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial cancer. Genetics and ovarian carcinoma. Immunotherapy and radiation combinatorial trials in gynecologic cancer: a potential synergy? View research View latest news Sign up for updates.
© 2020 movienewsfirst.com - All rights reserved. All Models are over 21 y.o.